📊 ATXI Key Takeaways
Investment Thesis
Avenue Therapeutics is a pre-revenue pharmaceutical company with severe operational losses and minimal commercialization progress. With only $1.4M in revenue against $2.3M in operating losses and rapidly depleting cash despite solid cash position, the company faces critical funding pressure and lacks evidence of viable product traction.
ATXI Strengths
- Maintains positive cash position of $3.7M providing near-term runway
- Zero long-term debt indicating no financial leverage burden
- Current ratio of 2.78x demonstrates adequate short-term liquidity
ATXI Risks
- Operating margin of -166% and net margin of -157% indicate unsustainable unit economics
- Negative free cash flow of -979K annually will exhaust cash reserves within 3-4 years at current burn rate
- Revenue of only $1.4M against operating losses suggests early-stage commercialization failure or product market fit issues
- Negative ROE of -61.8% and ROA of -59.1% show destruction of shareholder capital
- Single Form 4 filing in 90 days provides limited visibility into insider confidence
Key Metrics to Watch
- Quarterly revenue growth trajectory and product commercialization milestones
- Monthly cash burn rate and runway remaining before funding need
- Operating expense structure and path to break-even timing
ATXI Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.78x current ratio provides a solid financial cushion.
ATXI Profitability Ratios
ATXI vs Healthcare Sector
How AVENUE THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
ATXI Balance Sheet & Liquidity
ATXI 5-Year Financial Trend
5-Year Trend Summary: AVENUE THERAPEUTICS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.31 indicates the company is currently unprofitable.
ATXI Growth Metrics (YoY)
ATXI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$683.0K | $-0.21 |
| Q2 2025 | N/A | $335.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ATXI Capital Allocation
ATXI SEC Filings
Access official SEC EDGAR filings for AVENUE THERAPEUTICS, INC. (CIK: 0001644963)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATXI
What is the AI rating for ATXI?
AVENUE THERAPEUTICS, INC. (ATXI) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATXI's key strengths?
Maintains positive cash position of $3.7M providing near-term runway. Zero long-term debt indicating no financial leverage burden.
What are the risks of investing in ATXI?
Operating margin of -166% and net margin of -157% indicate unsustainable unit economics. Negative free cash flow of -979K annually will exhaust cash reserves within 3-4 years at current burn rate.
What is ATXI's revenue and growth?
AVENUE THERAPEUTICS, INC. reported revenue of $1.4M.
Does ATXI pay dividends?
AVENUE THERAPEUTICS, INC. does not currently pay dividends.
Where can I find ATXI SEC filings?
Official SEC filings for AVENUE THERAPEUTICS, INC. (CIK: 0001644963) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATXI's EPS?
AVENUE THERAPEUTICS, INC. has a diluted EPS of $-1.54.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.